NEUROENDOCRINE TUMOR G2
Clinical trials for NEUROENDOCRINE TUMOR G2 explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE TUMOR G2 trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE TUMOR G2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for slowing advanced neuroendocrine tumors in Final-Stage trial
Disease control OngoingThis study is testing whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors better than a placebo in people whose cancer has continued to worsen despite prior treatments. About 298 participants with specific advanced neuroendocrine tumors will be ran…
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Major cancer trial tests new drug duos for rare, aggressive tumors
Disease control OngoingThis large Phase 3 trial aims to find the better treatment combination for patients with advanced, high-risk neuroendocrine tumors (like carcinoid tumors) that have spread. Researchers are comparing a standard drug (octreotide) paired with either interferon or bevacizumab to see …
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial aims to halt rare Cancer's spread
Disease control OngoingThis study is testing whether a drug called pazopanib can slow or stop the growth of carcinoid tumors that are getting worse. It compares pazopanib against a placebo (inactive pill) in 171 patients whose tumors have progressed. The main goal is to see if the drug helps patients l…
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC